relatlimab (Opdualag) Report issue

Biologics mAb Approved FDA

Active Ingredient History

NOW
  • Now
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Combination drugs

( nivolumab (opdivo), relatlimab (Opdualag) - other name: nivolumab and relatlimab-rmbw )

Organizations (11)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (1)


 

Melanoma (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Chordoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Esophagogastric Junction (Phase 2)

Fallopian Tube Neoplasms (Phase 1/Phase 2)

Hamartoma (Phase 1/Phase 2)

Immune Checkpoint Inhibitors (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Melanoma (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 1/Phase 2)

Sarcoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 37
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue